RESULTS FOR : 'Genomics'
Showing 1 to 17 of 17 results |    
Keyword Search
Show#
Show#
Results Category/Section
ERS Genomics licenses CRISPR gene editing technology

ERS Genomics licenses CRISPR gene editing technology to Bioneer to further advance preclinical disease modelling.

Loop Genomics launches four new Microbiome kits

Loop Genomics launches four new Microbiome kits leveraging their ability to perform long-reads on Illumina sequencers.

From Genotype to Phenotype: Leveraging functional genomics in oncology

A challenge in drug discovery is that, at best, only around one in five drug candidates will lead to the launch of a medicine.

The role of toxicogenomics in drug discovery

The information that toxicogenomics can bring in terms of toxic mechanisms, safety and efficacy must ultimately have a major impact on the drug discovery process.

Pharmacogenomics - A new paradigm for drug development

Pharmacogenomics offers the opportunity to adopt a new paradigm in drug development. The pharmaceutical industry is faced with a number of challenges including relatively low productivity and success in bringing new drugs to market.

The Impact of Genomics on Regulation

Advances in science and technology are enabling us to understand physiology and pathology at a totally new level; to define, subtype and track diseases much more accurately; and to treat patients far more effectively, using novel delivery mechanisms and devices.

Metabolomics - A Playbook for Functional Genomics

If we have learned anything from scientific research in the last 20 years, it is that finding cures to complex diseases is difficult. Despite the promise of the genomic revolution, disease progression and patient outcomes are still not easily predicted by genetic factors alone.

Editing the Human Genome: Role in Functional Genomics and Translational Medicine

It is now readily accepted that we are in a post genomic era. With the steady flow of genomic information available to researchers worldwide, the focus turns to ways to analyse this information effectively and then utilise it in a practical manner.

Target discovery and drug design: extracting the value from genomics

Pharmaceutical research and development is changing. The old model of drug discovery, based on a combination of imprecise candidate generation and broad physiological screens, has given way to more specific and intelligent approaches to target identification and drug design.

The promise of pharmacogenetics and pharmacogenomics

Within the next 10 years the benefits of pharmacogenetics and pharmacogenomics will inevitably outweigh the disadvantages. But what are the commercial and legal implications for the pharmaceutical industry especially for companies who have lead candidates ready to enter development?

Chemogenomics - A gene family approach to parallel drug discovery

Currently available drugs only target around 500 different proteins (4). Recent reports from efforts to sequence the human genome suggest there are tens of thousands of genes (1,2) and many more different proteins.

Toxicogenomics - Insights into the present and future

Adverse drug responses are an important post-marketing public health issue, occurring many times in subsets of treatment populations. Promising new approaches to predicting physiological responses to drugs are focused on genomic responses or toxicogenomics (1).

The emergence of pharmacogenomics within the pharmaceutical industry

The sequencing of the human genome represents one of the most significant scientific advances of the 20th century that will shape the foundation of medical research well into the 21st.

High throughput genomics and drug discovery - parallel universes or a continuum?

HTS has been in place for approximately 10-12 years and has achieved a threeorder of magnitude scale up. Genomics has been in a 'high throughput' mode for approximately four years for areas such as genotyping, is an emerging field governed by sporadic technology leaps and data generation leaps.

Drug development for skin diseases based on functional genomics

With the high number of sufferers from skin disease around the world, it is astonishing that there are relatively few treatments available and that many of these only serve to relieve symptoms. Can drug development based on a functional genomics approach be the answer in bringing new products to this 'Cinderella' market?

Tools for Structural Genomics - Accelerating the structure pipeline

The international structural genomics effort has resulted in a number of technological advancements that are accelerating the process of threedimensional structure determination while continually decreasing the cost per structure.

Structural Genomics drives demand for high throughput protein purification

The rapid growth in proteomic and structural and functional genomic research is driving demand for purified proteins that far exceeds the industry's ability to scale-up conventional protein production technologies.